Consensus on the prevention of type 2 diabetes in Chinese adults

Chinese Medical Journal

Volumn 130, Issue 5, 2017, Pages 600-606

  Tong, Yu Zhen ^a   Tong, Nan Wei ^a   Teng, Wei Ping ^b   Mu, Yi Ming ^c   Zhao, Jia Jun ^d   Shan, Zhong Yan ^b   Ning, Guang ^e  

^a SICHUAN UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c Chinese Peoples Liberation Army General Hospital   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Adult; Consensus; Prediabetes; Prevention; Type 2 Diabetes

Indexed keywords

ACARBOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHINA; CONSENSUS DEVELOPMENT; DIABETIC MICROANGIOPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEALTH EDUCATION; HUMAN; HYPERGLYCEMIA; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MORTALITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ANALYSIS; CONSENSUS; GLUCOSE INTOLERANCE; IMPAIRED GLUCOSE TOLERANCE;

ACARBOSE; BLOOD GLUCOSE; CONSENSUS; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HUMANS; METFORMIN; PREDIABETIC STATE;

EID: 85013460208     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.4103/0366-6999.200532     Document Type: Article

References (53)

1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090-101. doi: 10.1056/NEJMoa0908292.
2. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013; 310: 948-58. doi: 10.1001/ jama.2013.168118.
3. The 13th Annual National Conference of Endocrinology, Chinese Medical Association (August 2013, Xi’an): Conference Materials; 2013.
4. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36: S11-66. doi: 10.2337/ dc13-s011.
5. Zhang S, Ren W, Rong L, Gong L, Li G, Li Q, et al. The best cut point of IFG and effects of its change on the statues of metabolism among Chongqing adults in China (in Chinese). Chin J Diabetes 2006; 14: 43-6. doi: 10.3321/j.issn: 1006-6187.2006.01.018.
6. Li X, Feng B, Ni Y, Huang Y, Le X, Fu M, et al. Influence of the new cut point of impaired fasting glucose on the distribution of IGR in Shanghai urban population (in Chinese). Chin J Diabetes 2006; 14: 119-20.
7. Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H, et al. Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 2010; 47: 231-6. doi: 10.1007/s00592-009-0143-2.
8. Su H, Pan C, Liu M, Jin M. Association between fasting plasma glucose and the 5 years outcome post PCI in aged patients with coronary artery disease (in Chinese). Chin J Cardiovasc Dis 2008; 36: 710-3. doi: 10.3321/j.issn: 0253-3758.2008.08.009.
9. Yang Z, Yang W, Xiao J, Li G, Wang Y. Impact of lowering the cut-point for impaired fasting glucose on the distribution of impaired glucose regulation subcategories in Chinese adult population (in Chinese). Natl Med J Chin 2004; 21: 1773-6. doi: 10.3760/j: issn: 0376-2491.2004.21.005.
10. Wang X, Lu J, Pan C, Tian H. The effect of the down regulation of diagnostic criteria for impaired fasting glucose on the detection rate of the impaired glucose regulation subjects (in Chinese). Chin J Diabetes 2005; 13: 265-8. doi: 10.3321/j.issn: 1006-6187.2005.04.011.
11. Somannavar S, Ganesan A, Deepa M, Datta M, Mohan V. Random capillary blood glucose cut points for diabetes and pre-diabetes derived from community-based opportunistic screening in India. Diabetes Care 2009; 32: 641-3. doi: 10.2337/dc08-0403.
12. Tanne D, Koren-Morag N, Goldbourt U. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: A prospective cohort study. Stroke 2004; 35: 2351-5. doi: 10.1161/01. str.0000140738.94047.55.
13. Yeboah J, Bertoni AG, Herrington DM, Post WS, Burke GL. Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2011; 58: 140-6. doi: 10.1016/j.jacc.2011.03.025.
14. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116: 151-7. doi: 10.1161/circulationaha.106.685628.
15. Oizumi T, Daimon M, Jimbu Y, Wada K, Kameda W, Susa S, et al. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample-The Funagata study. Metabolism 2008; 57: 333-8. doi: 10.1016/j.metabol.2007.10.007.
16. Vermeer SE, Sandee W, Algra A, Koudstaal PJ, Kappelle LJ, Dippel DW; Dutch TIA Trial Study Group. Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke. Stroke 2006; 37: 1413-7. doi: 10.1161/01.str.0000221766.73692.0b.
17. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study. Lancet 2008; 371: 1783-9. doi: 10.1016/ s0140-6736 (08) 60766-7.
18. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study. Lancet 2002; 359: 2140-4. doi: 10.1026/s0140-6736 (02) 09089-x.
19. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: A systematic review of the evidence. J Am Coll Cardiol 2010; 55: 1310-7. doi: 10.1016/j.jacc.2009.10.060.
20. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose (Summary) [EB/OL]. Agency for Healthcare Research and Quality (US) Evidence Report/ Technology Assessment; 2005. p. 1-11.
21. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-4. doi: 10.2337/diacare.22.6.920.
22. Yang Z, Xing X, Xiao J, Lu J, Weng J, Jia W, et al. Prevalence of cardiovascular disease and risk factors in the Chinese population with impaired glucose regulation: The 2007-2008 China national diabetes and metabolic disorders study (in Chinese). Exp Clin Endocrinol Diabetes 2013; 121: 372-4. doi: 10.1055/s-0033-1341520.
23. Sun Y, Chang P, Gao WG, Zhang D, Wang S, Qiao Q. Outcomes of normal glucose tolerance and impaired glucose regulation after 3 years follow-up in a population without diabetes mellitus (in Chinese). Chin J Public Health 2012; 28: 1393-5.
24. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract 2008; 14: 933-46.
25. Du Q, Shi F, Ding Q, Li Z, Song Y, Jia F. Natural outcome and risk factors of impaired fasting glucose and impaired glucose tolerance: A study of two-year follow-up and the related risk factor analysis (in Chinese). Chin J Endocrinol Metab 2004; 20: 223-6. doi: 10.3760/j. issn: 1000-6699.2004.03.015.
26. Plantinga LC, Crews DC, Coresh J, Miller ER 3rd, Saran R, Yee J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010; 5: 673-82. doi: 10.2215/CJN.07891109.
27. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007; 24: 137-44. doi: 10.1111/j.1464-5491.2007.02043.x.
28. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: The MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31: 464-9. doi: 10.2337/dc07-1796.
29. Panzer C, Lauer MS, Brieke A, Blackstone E, Hoogwerf B. Association of fasting plasma glucose with heart rate recovery in healthy adults: A population-based study. Diabetes 2002; 51: 803-7. doi: 10.2337/diabetes.51.3.803.
30. Putz Z, Tabák AG, Tóth N, Istenes I, Németh N, Gandhi RA, et al. Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. Diabetes Care 2009; 32: 181-3. doi: 10.2337/dc08-1406.
31. Zhou XH, Qiao Q, Zethelius B, Pyörälä K, Söderberg S, Pajak A, et al. Diabetes, prediabetes and cancer mortality. Diabetologia 2010; 53: 1867-76. doi: 10.1007/s00125-010-1796-7.
32. Dankner R, Chetrit A, Segal P. Glucose tolerance status and 20 year cancer incidence. Isr Med Assoc J 2007; 9: 592-6.
33. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003; 157: 1092-100. doi: 10.1093/aje/kwg100.
34. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease. Diabetes 2007; 56: 211-6. doi: 10.2337/db06-0879.
35. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 Suppl 1: S14-80. doi: 10.2337/ dc14-s014.
36. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract 2016; 22: 84-113. doi: 10.4158/EP151126.CS.
37. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR; Australian Diabetes Society; Australian Diabetes Educators Association. Prediabetes: A position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007; 186: 461-5.
38. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289-97. doi: 10.1007/s00125-005-0097-z.
39. Ke J. A clinical trial of treating impaired fasting glycaemia by metformin. Medicine industry information (in Chinese). China Med Her 2006; 17: 32-3.
40. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403. doi: 10.1056/NEJMoa012512.
41. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65. doi: 10.1016/S0140-6736 (98) 07037-8.
42. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43. doi: 10.1056/NEJMoa066224.
43. Yang W, Liu J, Shan Z, Tian H, Zhou Z, Ji Q, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: An open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol 2014; 2: 46-55. doi: 10.1016/ S2213-8587 (13) 70021-4.
44. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7. doi: 10.1016/S0140-6736 (02) 08905-5.
45. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003; 290: 486-94. doi: 10.1001/ jama.290.4.486.
46. Yang W, Lin L, Qi J, Yu Z, Pei H, He G, et al. The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: A 3 year multi-central prospective study (in Chinese). Chin J Endocrinol Metab 2001; 17: 131-4.
47. The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006; 368: 1096-105. doi: 10.1016/ S0140-6736 (06) 69420-8.
48. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 1104-15. doi: 10.1056/ NEJMoa1010949.
49. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: A consensus on Type 2 diabetes prevention. Diabet Med 2007; 24: 451-63. doi: 10.1111/j.1464-5491.2007.02157.x.
50. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 2007; 30 Suppl 1: S4-S41. doi: 10.2337/ dc07-S004.
51. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with EASD. Eur Heart J 2013; 34: 3035-87. doi: 10.1093/eurheartj/eht108.
52. Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: The China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011; 54: 300-7. doi: 10.1007/ s00125-010-1948-9.
53. Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: A 23-year follow-up study. Lancet Diabetes Endocrinol 2014; 2: 474-80. doi: 10.1016/ S2213-8587 (14) 70057-9.